1 | Increase in frequency of bowel movements < 4x above baseline; mild increase in ejection via stoma | Asymptomatic; clinical or diagnostic observation only; no action required |
2 | Increase in frequency of bowel movements 4–6x above baseline; moderate increase in ejection via stoma | Abdominal pain; mucus or blood in stool |
3 | Increase in frequency of bowel movements ≥ 7x above baseline, incontinence, need for hospitalisation, impaired daily self-care; marked increase in ejection via stoma | Severe or persistent abdominal pain; change in bowel movements; fever, ileus, peritoneal irritation; medical intervention required |
4 | Life-threatening consequences; need for urgent action | Life-threatening consequences; need for urgent action |
5 | Death | Death |
Disease activity | Inactive disease | Mild activity erythema, decreased vascular pattern, mild friability | Medium activity marked erythema, absent vascular pattern, friability, erosions | High activity |
Features | normal mucosa | spontaneous bleeding, ulceration |
Stool culture for pathogenic bacteria ( |
Clostridium difficile toxin |
Parasites and parasite eggs |
Pancreatic elastase |
Inflammatory markers (calprotectin, lactoferrin) |
PCR for CMV |
Complete blood count |
Biochemical tests (liver tests, renal function tests, amylase, lipase, albumin,...) |
TSH |
Inflammatory markers (CRP, ESR) |
Serology for celiac disease (total IgA, tTG) |
HIV serology |
CT scan of the abdomen (for severe abdominal pain) |
Endoscopy of the lower GI tract (in all or at least patients with CTCAE grade ≥ 2) |
Serology for HAV, HBV and HCV, HIV |
Quantiferon test |
Chest X-ray |